神经退行加速了吗? 通过功能连接研究COVID-19对痴呆症的影响
Aynur Müdüroğlu Kırmızıbekmez1, Alparslan Önder2, Mustafa Yasir Özdemir2,3
1Department of Basic Science, İstanbul Nisantasi University, İstanbul, Türkiye.
Noro psikiyatri arsivi
|September 15, 2025
概括
在痴呆症患者中,COVID-19显著降低了大脑连接,感染者显示出更大的下降. 这表明病毒可能会加速神经退行和认知障碍,强调需要进一步研究长期影响.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 传染性疾病 传染性疾病
背景情况:
- COVID-19与神经问题有关,包括认知缺陷.
- COVID-19对痴呆症患者大脑连接的影响尚不清楚.
- 系统性炎症,BBB功能障碍和神经炎症可能会导致COVID-19后的认知能力下降.
研究的目的:
- 为了调查在痴呆症患者和没有COVID-19病史的痴呆症患者之间跨频段的功能性大脑连接差异.
- 将患有 (D-COVID) 和没有 (D-nCOVID) COVID-19 病史的痴呆患者与健康对照 (HC) 进行比较.
- 探索COVID-19是否通过破坏大脑网络来加速神经退行.
主要方法:
- 基于脑电图 (EEG) 的网络分析被用来评估功能连接.
- 包括当地效率 (LE) 在内的连接指标在D-COVID,D-nCOVID和HC组之间进行了比较.
- 统计分析使用了克鲁斯卡尔-瓦利斯和恩测试.
主要成果:
- 痴呆症患者表现出功能连接性减少,而D-COVID患者表现出更显著的下降.
- 与痴呆症组相比,健康对照组显示出更强的连接性和更高的LE指标.
- 这些发现表明,COVID-19可能通过破坏大脑网络来加剧神经退行性过程.
结论:
- 通过恶化神经退行机制,COVID-19似乎有助于认知衰退.
- 在D-COVID患者中功能连接的破坏支持了SARS-CoV-2间接促进神经元退化的假设.
- 纵向研究对于了解长期认知影响和开发干预措施至关重要.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Disorders of the Nervous Tissue
2.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.5K
Neuroplasticity
1.6K
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
1.6K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K


